David Assouline

3.5k total citations
22 papers, 410 citations indexed

About

David Assouline is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Assouline has authored 22 papers receiving a total of 410 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pathology and Forensic Medicine and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Assouline's work include Lymphoma Diagnosis and Treatment (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Acute Myeloid Leukemia Research (3 papers). David Assouline is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Lung Cancer Treatments and Mutations (5 papers) and Acute Myeloid Leukemia Research (3 papers). David Assouline collaborates with scholars based in France, Belgium and United States. David Assouline's co-authors include M. Sextro, R T Hoppe, D Fière, Richard I. Fisher, Daniel Crowther, Volker Diehl, S Pavlovsky, AA Bartolucci, Peter H. Wiernik and Oana Brosteanu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

David Assouline

21 papers receiving 396 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Assouline France 9 227 184 119 74 68 22 410
Richard Bakemeier United States 14 130 0.6× 158 0.9× 125 1.1× 72 1.0× 55 0.8× 35 543
Jill Moormeier United States 11 128 0.6× 230 1.3× 46 0.4× 71 1.0× 35 0.5× 24 473
S.A.M. van de Schans Netherlands 14 209 0.9× 247 1.3× 115 1.0× 68 0.9× 50 0.7× 26 462
Christine Laidlaw Australia 11 119 0.5× 157 0.9× 80 0.7× 36 0.5× 52 0.8× 21 353
Eugenia Piliotis Canada 12 180 0.8× 306 1.7× 55 0.5× 100 1.4× 84 1.2× 30 567
C.A. Uyl-de Groot Netherlands 12 116 0.5× 258 1.4× 54 0.5× 71 1.0× 49 0.7× 28 553
Grenfell Adams Canada 5 198 0.9× 172 0.9× 95 0.8× 71 1.0× 69 1.0× 7 355
Joseph Weiner United States 15 93 0.4× 134 0.7× 241 2.0× 77 1.0× 44 0.6× 42 620
William G. Swartz United States 10 260 1.1× 166 0.9× 24 0.2× 98 1.3× 36 0.5× 12 465
Chiara Broglia Italy 13 396 1.7× 248 1.3× 147 1.2× 184 2.5× 118 1.7× 20 662

Countries citing papers authored by David Assouline

Since Specialization
Citations

This map shows the geographic impact of David Assouline's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Assouline with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Assouline more than expected).

Fields of papers citing papers by David Assouline

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Assouline. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Assouline. The network helps show where David Assouline may publish in the future.

Co-authorship network of co-authors of David Assouline

This figure shows the co-authorship network connecting the top 25 collaborators of David Assouline. A scholar is included among the top collaborators of David Assouline based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Assouline. David Assouline is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Coeffic, David, Carolina Castillo, Catherine Sebban, et al.. (2010). Use of chemotherapy and immunotherapy in the last two months of life in a French institutional anticancer center, 2008-2009.. Journal of Clinical Oncology. 28(15_suppl). e19656–e19656. 1 indexed citations
4.
Gressin, Rémy, Steven Le Gouill, Mario Ojeda‐Uribe, et al.. (2008). Interim Results of the RiPAD+C Regimen Including Velcade in Front Line Therapy for Elderly Patients with Mantle Cell Lymphoma. A Phase II Prospective Study of the GOELAMS Group.. Blood. 112(11). 1575–1575. 7 indexed citations
5.
Page, E, David Assouline, Catherine Durand, et al.. (2006). Stage-related changes in functional capacity in Hodgkin’s disease: assessment by cardiopulmonary exercise testing before initiation of treatment. Annals of Hematology. 85(12). 857–861. 4 indexed citations
6.
Ray‐Coquard, Isabelle, Thomas Bachelot, Jean‐Paul Guastalla, et al.. (2003). Epirubicin and paclitaxel (EPI-TAX regimen) for advanced ovarian cancer after failure of platinum-containing regimens. Gynecologic Oncology. 88(3). 351–357. 7 indexed citations
7.
Douillard, Jean‐Yves, D. Lerouge, Alain Monnier, et al.. (2001). Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study. British Journal of Cancer. 84(9). 1179–1184. 26 indexed citations
8.
Douillard, Jean‐Yves, et al.. (2000). Phase II study with Taxol® (paclitaxel) and Gemzar® (gemcitabine) in metastatic non-small cell lung cancer (NSCLC). Lung Cancer. 29(1). 45–46. 2 indexed citations
9.
Belhabri, Amine, Xavier Thomas, Jacques Troncy, et al.. (1999). Continuous-Infusion Carboplatin in Combination with Idarubicin or Mitoxantrone for High-Risk Acute Myeloid Leukemia: A Randomised Phase II Study. Leukemia & lymphoma. 36(1-2). 45–55. 5 indexed citations
10.
Exbrayat, C., Anne Garnier, Maria Antonietta Colonna, et al.. (1999). Analysis and classification of interval cancers in a French breast cancer screening programme (départment of Isère). European Journal of Cancer Prevention. 8(3). 255–260. 18 indexed citations
11.
Loeffler, Markus, Oana Brosteanu, Dirk Hasenclever, et al.. (1998). Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group.. Journal of Clinical Oncology. 16(3). 818–829. 143 indexed citations
12.
Thomas, X., Jacques Troncy, David Assouline, et al.. (1997). Serum Interleukin-6 Levels in Adult Acute Myelogenous Leukemia: Relationship with Disease Characteristics and Outcome. Leukemia & lymphoma. 24(3-4). 291–300. 13 indexed citations
13.
Fermé, Christophe, Y Bastion, Pauline Brice, et al.. (1997). Prognosis of patients with advanced hodgkin's disease. Cancer. 80(6). 1124–1133. 1 indexed citations
14.
Bastion, Y, Pauline Brice, P Lederlin, et al.. (1997). Prognosis of patients with advanced hodgkin's disease. Cancer. 80(6). 1124–1133. 25 indexed citations
15.
Lebranchu, Yvon, Jacques Dantal, J Bedrossian, et al.. (1996). HODGKIN'S DISEASE AFTER TRANSPLANTATION1. Transplantation. 61(1). 71–76. 44 indexed citations
16.
Assouline, David, et al.. (1996). De l'usine au maquis. Medical Entomology and Zoology. 1 indexed citations
17.
Sebban, Catherine, George P. Browman, Amiram Gafni, et al.. (1995). Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia. American Journal of Hematology. 48(4). 221–227. 47 indexed citations
18.
Bastion, Y, Bertrand Coiffier, Pascale Felman, et al.. (1990). Massive mediastinal extramedullary hematopoiesis in hereditary spherocytosis: A case report. American Journal of Hematology. 35(4). 263–265. 15 indexed citations
19.
Sobol, Hagay, Steven A. Narod, David Assouline, Gilbert Lenoir, & C Calmettes. (1989). Genetic Screening of Endocrine Tumour Syndromes with DNA Probes: The Example of Medullary Thyroid Carcinoma. Hormone Research. 32(1-3). 34–40. 2 indexed citations
20.
Assouline, David, et al.. (1989). [Cardiotoxicity of 5 fluoro-uracil. Apropos of a case].. PubMed. 6(6). 551–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Bakemeier Breakdown of academic impact, for papers by Jill Moormeier Breakdown of academic impact, for papers by S.A.M. van de Schans Breakdown of academic impact, for papers by Christine Laidlaw Breakdown of academic impact, for papers by Eugenia Piliotis Breakdown of academic impact, for papers by C.A. Uyl-de Groot Breakdown of academic impact, for papers by Grenfell Adams Breakdown of academic impact, for papers by Joseph Weiner Breakdown of academic impact, for papers by William G. Swartz Breakdown of academic impact, for papers by Chiara Broglia
Rankless by CCL
2026